Stay updated with breaking news from Keith Syson Chan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers found that because the novel drug combination of an anti-inflammatory medication like celecoxib, chemotherapy and immunotherapy potentially can increase the chemoimmunotherapy response in patients with muscle-invasive bladder cancer. Each year, more than 83,000 new U.S. cases of bladder cancer are diagnosed in men and women. About one quarter of those newly diagnosed have the muscle-invasive type.
Adding an anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumor growth, according to a proof-of-concept study led by Cedars-Sinai Cancer investigators.
Chemotherapy Poised to Deliver a Double Punch Source: Rita Serda and NIH December 9, 2020 Share A new study provides an explanation as to why cancer immunotherapy currently fails in many patients and offers a potential solution that could increase the efficacy of anticancer drugs. Currently, 70 to 85% of patients taking immunotherapy drugs fail to respond to them. Kazukuni Hayashi, PhD In the study conducted on laboratory mice, Kazukani Hayashi, PhD, and a team of cancer researchers at Cedars-Sinai, showed that combining the chemotherapy drug, Gemcitabine, with the anti-inflammatory drug, Ce...